Analysts Set EXACT Sciences Co. (EXAS) Price Target at $52.36

EXACT Sciences Co. (NASDAQ:EXAS) has been assigned a consensus rating of “Buy” from the eighteen analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $52.36.

A number of equities analysts recently issued reports on EXAS shares. BTIG Research raised EXACT Sciences from a “neutral” rating to a “buy” rating in a report on Tuesday, April 3rd. ValuEngine raised EXACT Sciences from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. William Blair reissued a “buy” rating on shares of EXACT Sciences in a report on Thursday, March 29th. Zacks Investment Research lowered EXACT Sciences from a “buy” rating to a “hold” rating in a report on Friday, January 19th. Finally, Benchmark lowered EXACT Sciences from a “buy” rating to a “hold” rating in a report on Friday, February 23rd.

Shares of EXACT Sciences traded up $1.24, hitting $52.36, during mid-day trading on Monday, MarketBeat Ratings reports. 1,299,830 shares of the stock were exchanged, compared to its average volume of 2,314,598. The firm has a market cap of $6.23 billion, a price-to-earnings ratio of -52.89 and a beta of 0.86. EXACT Sciences has a 12-month low of $30.17 and a 12-month high of $63.60. The company has a debt-to-equity ratio of 0.71, a quick ratio of 14.86 and a current ratio of 15.30.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Thursday, April 26th. The medical research company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.05. The company had revenue of $90.30 million for the quarter, compared to analyst estimates of $86.31 million. EXACT Sciences had a negative return on equity of 20.92% and a negative net margin of 38.61%. The business’s quarterly revenue was up 86.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.32) earnings per share. research analysts predict that EXACT Sciences will post -1.11 EPS for the current year.

In related news, SVP D Scott Coward sold 2,122 shares of the firm’s stock in a transaction dated Monday, April 2nd. The shares were sold at an average price of $40.12, for a total value of $85,134.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Maneesh Arora sold 5,295 shares of the firm’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $52.19, for a total transaction of $276,346.05. The disclosure for this sale can be found here. In the last 90 days, insiders sold 135,748 shares of company stock valued at $6,082,759. 4.00% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in EXAS. OppenheimerFunds Inc. lifted its position in EXACT Sciences by 99.6% in the first quarter. OppenheimerFunds Inc. now owns 5,831,347 shares of the medical research company’s stock valued at $235,179,000 after purchasing an additional 2,910,506 shares during the period. Artisan Partners Limited Partnership acquired a new stake in EXACT Sciences in the first quarter valued at about $60,243,000. Carillon Tower Advisers Inc. acquired a new stake in EXACT Sciences in the fourth quarter valued at about $66,280,000. Victory Capital Management Inc. lifted its position in EXACT Sciences by 82.9% in the fourth quarter. Victory Capital Management Inc. now owns 1,189,560 shares of the medical research company’s stock valued at $62,499,000 after purchasing an additional 539,160 shares during the period. Finally, Atlantic Trust Group LLC lifted its position in EXACT Sciences by 423.8% in the first quarter. Atlantic Trust Group LLC now owns 625,906 shares of the medical research company’s stock valued at $25,244,000 after purchasing an additional 506,404 shares during the period. Hedge funds and other institutional investors own 82.64% of the company’s stock.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply